Clinical trial · Interventional
Michigan Genetic Hereditary Testing (MiGHT)
Methods for Increasing Genetic Testing Uptake in Michigan
NCT05162846CI-TRIAL-00122433MiGHTcompletedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase the likelihood of a participant obtaining guideline-concordant genetic testing. Eligible participants will be randomized (assigned) to one of the following interventions: 1) Virtual genetics navigator, a mobile-optimized website, designed by the investigators, that delivers tailored messages and content; 2) two motivational interviewing (MI) telephone calls delivered by trained genetics health coaches; or 3) usual care.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
| History of Cancer | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Motivational interviewing (MI) | Behavioral | — | UNRESOLVED |
| Publicly available genetic testing resources | Other | — | UNRESOLVED |
| Virtual genetics navigator | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Arm 1 - Usual care (UC)
- description
- Participants are provided with a link to the Michigan Department of Health and Human Services (MDHHS) informational website and are instructed to follow up with their oncology provider about genetic testing.
- interventionNames
- Other: Publicly available genetic testing resources
- type
- EXPERIMENTAL
- label
- Arm 2 - Virtual genetics navigator
- description
- Participants receive access to an online genetics tool, the virtual genetics navigator, to help learn why and how to seek out genetic testing for hereditary cancer syndromes.
- interventionNames
- Behavioral: Virtual genetics navigator
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* Able to speak and read English
* Access to the internet
* Completed the Family Health History Tool (FHHT)
* Meeting clinical criteria for genetic evaluation due to any of the below:
1. Personal history of Breast cancer either:
* i. Diagnosed under 50
* ii. Personal or family history of triple negative breast cancer
* iii. Ashkenazi Jewish ancestry
* iv. Male proband
* v. 1st or 2nd degree relative with ovarian cancer, pancreatic cancer, breast cancer diagnosed under 50, or male breast cancer
2. Personal history of prostate cancer either:
* i. Diagnosed under 50
* ii. Ashkenazi Jewish ancestry
* iii. 1st or 2nd degree relative with ovarian cancer, pancreatic cancer, breast cancer diagnosed under 50, or male breast cancer
3. Personal history of any cancer or no personal history of cancer with either:
* i. PREMM score ≥ 2.5%
* ii. 1st degree relative with pancreatic, or male breast cancer
* iii. 1st or 2nd degree relative with ovarian cancer
* iv. 1st degree relative with any of these cancers diagnosed under 50: colon, endometrial, or breast
* v. Ashkenazi Jewish ancestry and 1st or 2nd degree relative with breast cancer
4. Personal history of endometrial cancer diagnosed under 50
5. Personal history of colorectal cancer diagnosed under 50
6. Personal history of renal cancer diagnosed under 46
7. Personal history of sarcoma diagnosed under 46 and a 1st or 2nd degree relative with sarcoma, breast cancer, or brain cancer diagnosed under 56
8. Personal history of brain cancer diagnosed under 46 and a 1st or 2nd degree relative with sarcoma, breast cancer, or brain cancer diagnosed under 56
9. Personal history of any two of the following cancers with at least one of them diagnosed under 46: breast, sarcoma, or brain
10. Personal history of ovarian cancer
11. Personal history of pancreatic cancer
12. Personal history of adrenal cortical carcinoma
Exclusion Criteria:
* Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics providerReferences
Publications (1)
- DERIVEDGerido LH, Griggs JJ, Resnicow K, Kidwell KM, Delacroix E, Austin S, Hanson EN, Bacon E, Koeppe E, Goodall S, Demerath M, Rizzo EA, Weiner S, Hawley ST, Uhlmann WR, Roberts JS, Stoffel EM. The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial. Trials. 2023 Feb 10;24(1):105. doi: 10.1186/s13063-023-07125-2. PMID 36765432